ADCT ADC Pharma Earnings per share growth rate in current year

Official company branding of ADC Pharma (ADCT)

The diversification of hematologic malignancy treatment programs in the US and Europe creates significant potential, as confirmed by the year-over-year EPS comparison for ADC Therapeutics (ADCT). Premium pricing driven by patents and stable demand for Zynlonta minimize operational risks. The current value of the indicator is 37.90, allowing for an objective assessment of real business dynamics and the avoidance of capital drawdown.

ADCT - ADC Therapeutics SA Earnings growth in current year over the range 07/04/2022 - 11/16/2026

Financial and market metric breakdowns for ADC Therapeutics S.A. (ADCT)

- stock value and consensus price forecast:
Summary company analysis:ADC Therapeutics (ADCT)
Brand item of ADC Therapeutics SA

Assessing asset reliability begins with analyzing the growth rates of net income per share, which reveals the actual efficiency of capital management. This calculation, reflecting the annual EPS growth in the context of Zynlonta's expansion in lymphoma therapy markets, determines the speed of innovation monetization, as clearly demonstrated by the annual net income per share dynamics for ADC Therapeutics (ADCT) on the GURU.Markets service.